Proteogenomics identifies c-Met inhibition as a therapeutic strategy for BAP1-deficient clear cell renal cell carcinoma.

ABSTRACT:

SUBMITTER: Du B 

PROVIDER: S-EPMC11555054 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature